The Impact of Untreated Attention-Deficit/Hyperactivity Disorder on Motor Vehicle Accidents: A Systematic Review and Meta-Analysis.

Adv TherMay 23, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Ann Childress, Hirah Malik, Jim Potenziano

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the relationship between untreated Attention-Deficit/Hyperactivity Disorder (ADHD) and motor vehicle accidents (MVAs). It found that untreated ADHD drivers have a 93% higher odds of being involved in accidents compared to the general driving population. The study analyzed data from four studies to quantify these risks.

Key findings

  • Untreated ADHD drivers have a 93% increased odds of accidents compared to the general population.
  • THC/cannabis users show an 85% increase in accident odds.
  • Sleepy or tired drivers have a 162% increase in accident odds.
  • Opioid or benzodiazepine users have a 53% increase in accident odds.

Why it matters

Understanding the heightened risk of motor vehicle accidents in untreated ADHD patients underscores the importance of diagnosis and treatment. Clinicians can play a crucial role in mitigating these risks through appropriate management strategies.

Source

PubMed · PMID 42176184Free full text on PubMed Central

Published in Adv Ther. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.